PD as well as MPTP treatment result in the degeneration of nigrostriatal DA neurons, which decreases DA release in the striatum and results in diminished activation of the DRD2 and DRD3 DA receptors, in turn affecting postsynaptic striatal protein expression and calcium signaling. Here, DRD2 is linked to Parkinson disease.